Hidden geometry explains why kernel methods separate complex data so well

Are two sets of data genuinely different, or is it because of randomness? This question, known as the two-sample testing problem, becomes notoriously difficult in modern datasets, because they are ...
Scientific American

Anthropic warns AI could soon start improving itself. Critics aren’t convinced

The maker of Claude wants AI labs, including itself, to prepare for a coordinated slowdown if models begin building their own ...

Jeff Bezos Is Funding a Wild Hunt for the Brain’s ‘Core Algorithm’

With $500 million in funding and a reported $2.5 billion valuation, Flourish wants to reinvent AI by putting real neurons ...
Seeking Alpha

RXRX Recursion Pharmaceuticals, Inc.

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
IEEE

New ℌ ∞ bounds for the recursive least squares algorithm exploiting input structure

Abstract: The recursive least squares (RLS) algorithm is well known and has been widely used for many years. Most analyses of RLS have assumed statistical properties of the data or the noise process, ...
STAT

Merck’s RSV drug approval and a drug manufacturer winds down

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...
Nasdaq

MIT and Recursion Unveil Boltz-2: A Revolutionary Open-Source Biomolecular Co-Folding Model with Advanced Structure and Binding Affinity Prediction

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...
Nasdaq

Recursion Deprioritizes 3 Clinical Programs Following Data-Driven Review, Stock Down

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...
BioSpace

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse events In comparison to placebo, treatment with REC-994 400 mg showed ...
TMCnet

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of ...

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of ...